Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raj Sengupta

Showing results (61-70 of 86) with videos related to

Pageof 9
Sort By:
Rheumatology Advances in Practice|August 15, 2020
Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational studyLiz Van Rossen, Antoni Chan, Annie Gilbert, et al.
Rheumatology (Oxford, England)|December 23, 2017
Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohortFariz Yahya, Karl Gaffney, Louise Hamilton, et al.
Rheumatology (Oxford, England)|December 19, 2024
BRITSpA at 10Helena Marzo-Ortega, Alexander N Bennett, Aisling Coy, et al.
Rheumatology Advances in Practice|August 22, 2019
Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort: replyFariz Yahya, Karl Gaffney, Louise Hamilton, et al.
Rheumatology (Oxford, England)|October 25, 2012
Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritisDeepak Jadon, William Tillett, Dinny Wallis, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|February 27, 2025
Delayed diagnosis of axial spondyloarthritis: the crucial role of primary care - how you can make a differenceThomas A Ingram, Joe Eddison, Karl Gaffney, et al.
Arthritis Research & Therapy|January 20, 2026
Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 yearsSofia Ramiro, Fabian Proft, Raj Sengupta, et al.
Clinical Medicine (London, England)|September 12, 2020
Evaluation of a patient self-stratification methodology to identify those in need of shielding during COVID-19Elizabeth Reilly, Sarah Skeoch, Sarah Hardcastle, et al.
BMC Rheumatology|May 31, 2019
AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS)Gary J Macfarlane, Ejaz Pathan, Stefan Siebert, et al.
Rheumatology (Oxford, England)|April 25, 2025
What is the economic burden of delayed axial spondyloarthritis diagnosis in the UK?Fernando Zanghelini, George Xydopoulos, Stephanie Howard Wilsher, et al.
Pageof 9

Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
Rheumatology Advances in Practice|August 15, 2020
Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational studyLiz Van Rossen, Antoni Chan, Annie Gilbert, et al.
Rheumatology (Oxford, England)|December 23, 2017
Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohortFariz Yahya, Karl Gaffney, Louise Hamilton, et al.
Rheumatology (Oxford, England)|December 19, 2024
BRITSpA at 10Helena Marzo-Ortega, Alexander N Bennett, Aisling Coy, et al.
Rheumatology Advances in Practice|August 22, 2019
Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort: replyFariz Yahya, Karl Gaffney, Louise Hamilton, et al.
Rheumatology (Oxford, England)|October 25, 2012
Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritisDeepak Jadon, William Tillett, Dinny Wallis, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|February 27, 2025
Delayed diagnosis of axial spondyloarthritis: the crucial role of primary care - how you can make a differenceThomas A Ingram, Joe Eddison, Karl Gaffney, et al.
Arthritis Research & Therapy|January 20, 2026
Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 yearsSofia Ramiro, Fabian Proft, Raj Sengupta, et al.
Clinical Medicine (London, England)|September 12, 2020
Evaluation of a patient self-stratification methodology to identify those in need of shielding during COVID-19Elizabeth Reilly, Sarah Skeoch, Sarah Hardcastle, et al.
BMC Rheumatology|May 31, 2019
AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS)Gary J Macfarlane, Ejaz Pathan, Stefan Siebert, et al.
Rheumatology (Oxford, England)|April 25, 2025
What is the economic burden of delayed axial spondyloarthritis diagnosis in the UK?Fernando Zanghelini, George Xydopoulos, Stephanie Howard Wilsher, et al.
Pageof 9